Engle Martin & Associates, LLC Announces Acquisition of EIMC, LLC
17.4.2023 15:00:00 EEST | Business Wire | Press release
Engle Martin & Associates, LLC ("Engle Martin"), a market-leading independent loss adjusting and claims management provider, announced today that it has acquired EIMC, LLC (“EIMC”), a leading global provider of ocean marine, risk management, claims investigation, and subrogation services based in Jersey City, New Jersey and London, England.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230417005197/en/
Founded in 1968, EIMC serves clients across the entire marine global supply chain with 50+ years of expertise in providing the full continuum of assessments, risk mitigation, and claim resolution solutions within marine cargo, stock throughout, hull & machinery, and fine art & specie. EIMC operates in 15 office locations strategically positioned in the United States and the United Kingdom. The organization works with a broad group of clients in all major international insurance markets and is also the Lloyd’s Agent for multiple locations in the United States. Since its inception, EIMC has been recognized by major international insurers and numerous insurance associations as a premier provider of marine insurance risk management and claims services.
This acquisition expands Engle Martin’s global footprint and diversifies its service portfolio by providing clients with a full suite of ocean marine services. This acquisition also provides EIMC an extensive back-office infrastructure, innovative technology solutions, and growth opportunities for team members. EIMC has a remarkable history within the maritime community that has resulted in distinctive and long-lasting relationships with its clients and carrier partners. EIMC’s leadership team will remain in place and will maintain operational oversight of their portfolio.
When asked about the acquisition, Jay Campbell, Executive Vice President of Strategy & Organizational Growth of Engle Martin, said “We are excited to continue growing and investing in our business. The acquisition expands our service capabilities in the ocean marine & technical risk services arena with an organization that is well-aligned with our culture and approach to business. We will continue to provide our clients with the same service, quality, and capabilities they have come to expect from our team, with a complementary service that allows us to respond to our customers in a holistic manner.”
Tiina Ruhlandt, Managing Director of EIMC, said “We are delighted that Engle Martin appreciates the value of our organization; and we are confident and excited that our combined expertise will have a positive impact on our continued growth and success. We believe that this partnership is an excellent extension of Engle Martin’s long-term business strategy, and we are thrilled to have a partner who shares our principles and respects the culture which has driven our success.”
About Engle Martin
Engle Martin is a market-leading independent loss adjusting and claims management provider. Engle Martin has a comprehensive business philosophy: to provide the best insurance claim adjustment results in the industry, present the most talented claims professionals, foster an innovative and professional leadership team, and develop client-focused solutions. The firm provides a comprehensive line of service offerings including commercial property, casualty, specialty marine and transportation, appraisal/umpire, specialty audits, carrier outsourcing, and claims management services. For details about industries served and services offered by Engle Martin, visit EngleMartin.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230417005197/en/
Contact information
Dominique Enriquez
Marketing Director
+1 678.553.3872
denriquez@englemartin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom